Genentech Releases SMA Community Letter
Our industry partners at Genentech recently released an SMA community letter summarizing 2022 developments and initiates. Check it out here!
Genentech Releases SMA Community Letter Read More »
Share Your Air Travel Concerns & Experiences for Cure SMA Report to Congress
The law that governs air travel in the United States is about to expire. Next year, Congress must consider air travel changes through a new Federal Aviation Administration (FAA) reauthorization bill. The last time the law was updated (2018), Congress included several provisions aimed at making air travel more accessible for people with disabilities. (For
Share Your Air Travel Concerns & Experiences for Cure SMA Report to Congress Read More »
SMA Community Progress & Advocacy Featured at Cure SMA Hope on the Hill Event
Congressional leaders and key partners, supporters, and members of the spinal muscular atrophy (SMA) community celebrated SMA achievements and advocacy at Cure SMA’s 11th Annual Hope on the Hill Congressional Event. Hope on the Hill is an annual event to increase awareness about SMA and recognize policymakers and other key partners for helping to advance
SMA Community Progress & Advocacy Featured at Cure SMA Hope on the Hill Event Read More »
Cure SMA to Host 11th Annual Hope on the Hill Event in Washington, D.C.
On December 6th, Cure SMA will highlight the progress made in spinal muscular atrophy (SMA) and recognize the advocacy that helped lead to this success in a special event in our nation’s capital. Cure SMA has hosted an annual Hope on the Hill congressional dinner and reception in Washington, D.C. since 2010 to increase awareness
Cure SMA to Host 11th Annual Hope on the Hill Event in Washington, D.C. Read More »
Biogen Releases Q3 SMA Community Statement
Learn about Biogen’s latest news in SMA by viewing their Community Statement and a related video.
Biogen Releases Q3 SMA Community Statement Read More »
The Giving Season is Here!
Cure SMA leads the way to a world where everyone impacted by SMA is empowered to lead their best lives. As 2022 comes to a close, we celebrate stories of breakthroughs powered by research and care, while also recognizing that our work is not done. This is Cure SMA’s commitment to our community. Key components
The Giving Season is Here! Read More »
Community Spotlight: Michelle Tynski and Family
Play is important for kids. It allows children to develop cognitive, social, emotional, and physical skills while engaging creatively. But it’s not just how kids play that’s important, what they play with also matters. Which is why Michelle Tynski, mom to nine-year-old Trace, Benjamin who passed away in 2016, and 3-year-old Zach, who has Type
Community Spotlight: Michelle Tynski and Family Read More »
Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)
Genentech, announced earlier this month new two-year data from the JEWELFISH study evaluating Evrysdi® (risdiplam) in people with Type 1, 2 or 3 SMA aged 6 months to 60 years at time of enrollment. Patients had been previously treated with other approved or investigational SMA-targeting therapies, including Spinraza® or Zolgensma®. Data showed Evrysdi improved or maintained motor function
SMA Community Seeks SSI Improvements on Program’s 50th Anniversary
Fifty years ago today, the Supplemental Security Income (SSI) program was created to “provide supplemental security income to individuals who have attained age 65 or are blind or disabled” for their basic living needs, such as housing, clothing, medical costs, and food. The program and its monthly cash benefit have been a lifeline for many
SMA Community Seeks SSI Improvements on Program’s 50th Anniversary Read More »
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
Scholar Rock yesterday announced new quality-of-life (QoL) data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment which indicate stabilization or continued improvement with apitegromab for nonambulatory patients with Types 2 and 3 spinal muscular atrophy (SMA) receiving an SMN-targeted therapy. The TOPAZ trial assessed activities of daily